Viral Vectors and Plasmid DNA Manufacturing Market size worth $ 1,866.90 Million, Globally, by 2028 at 15.40% CAGR: Verified Market Research®
The market is strongly supported by a robust pipeline for gene therapy and vector vaccines and technological advancements in manufacturing vectors. Enhancing in occurrence and frequency rates of cancer and high unmet patient needs with the unusual disorder are anticipated to boost the market growth.
Jersey City, New Jersey, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Viral Vectors and Plasmid DNA Manufacturing Market” By Product Type (Viral Vectors, Plasma DNA, Non-Viral DNA Vectors), By Application (Cancer, Inherited Disorder, Infectious Diseases, and Others), By End Product (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and By Geography. According to Verified Market Research, the Global Viral Vectors and Plasmid DNA Manufacturing Market size was valued at USD 583.71 Million in 2020 and is projected to reach USD 1,866.90 Million by 2028, growing at a CAGR of 15.40% from 2021 to 2028.
Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=39643
Browse in-depth TOC on “Viral Vectors and Plasmid DNA Manufacturing Market”
202 - Pages
126 – Tables
37 – Figures
Global Viral Vectors and Plasmid DNA Manufacturing Market Overview
A growing number of patients opting for gene therapy is a major factor propelling the growth of the Viral Vectors and Plasmid DNA Manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases. Genetically modified therapies have emerged as a promising treatment approach for various diseases (primarily ones that currently have no cure), including inherited disorders and certain viral infections. Demand for plasmid DNA is rising steeply because of a boom in gene therapy development. pDNA is a prerequisite for the production of AAV (adeno-associated virus), lentivirus, and other viral vector platforms. There is an increase in several genetic disorders and infectious diseases across the globe. For instance, according to the UNAIDS statistics, in 2019, 38.0 million individuals worldwide were living with HIV and 1.7 million people became newly infected with HIV.
Manufacturing challenges pertaining to the large-scale production of vectors might restrict the growth of the market. The global healthcare industry has experienced the augmented availability of technologically advanced healthcare equipment because of the growing investments from healthcare stakeholders in delivering innovative care delivery models, advanced digital technologies, and many others. This has ultimately assisted in developing an advanced health ecosystem across the globe. The up-surging healthcare infrastructure will create numerous opportunities in the sector which will ultimately improve the demand for viral vectors and plasmid DNA across the globe. However, regulatory, scientific, and ethical challenges associated with gene therapy, production capacity limitations, and manufacturing challenges pertaining to large-scale production of vectors are major aspects that limit the market growth.
Key Developments in Viral Vectors and Plasmid DNA Manufacturing Market
In January 2021, Thermo Fisher Scientific had acquired Viral Vector Manufacturing Business from Novasep.
In April 2020, Merck had announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance viral and gene therapy service offering.
In May 2021, Lonza launches Next Generation 4D-Nucleofector Cell Transfection Platform with proven performance and enhanced ease of use.
The major players in the market are Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience, Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, and Others.
Verified Market Research has segmented the Global Viral Vectors and Plasmid DNA Manufacturing Market On the basis of Product Type, Application, End Product, and Geography.
Viral Vectors and Plasmid DNA Manufacturing Market, By Product Type
Viral Vectors
Plasma DNA
Non-Viral DNA Vectors
Viral Vectors and Plasmid DNA Manufacturing Market, By Application
Cancer
Inherited Disorder
Infectious Diseases
Others
Viral Vectors and Plasmid DNA Manufacturing Market, By End-Product
DNA Vaccines
Gene Therapy
Immunotherapy
Others
Viral Vectors and Plasmid DNA Manufacturing Market by Geography
North America
U.S
Canada
Mexico
Europe
Germany
France
U.K
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
ROW
Middle East & Africa
Latin America
Browse Related Reports:
Viral Inactivation Market By Method (Solvent Detergent Method, Pasteurization), By Application (Vaccines and Therapeutics, Tissues and Tissue Products), By End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations), By Geography, Forecast, 2021-2028
Viral Clearance Market By Method (Viral Removal and Viral Inactivation), By Application (Recombinant Proteins, Blood and Blood Products, Vaccines), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), By Geography, Forecast, 2021-2028
Anti-Infective Agents Market By Product (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), By Application (Hospital Use, Clinic Use, Household), By Geography, Forecast, 2021-2028
Anti-Infective Drugs Market By Product (Antibiotics, Antivirals, and Antifungals), By Geography, Forecast, 2021-2028
Top 10 biopharmaceutical companies synthesizing biological sources for global patients
Visualize Viral Vectors and Plasmid DNA Manufacturing Market using Verified Market Intelligence:-:
Verified Market Intelligence is our BI Enabled Platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.
VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.
About Us
Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.
Our 250 Analysts and SME’s offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & Construction, Agriculture industry and Medical Devices from over 100 countries.
CONTACT: Mr. Edwyne Fernandes Verified Market Research® US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll Free: +1 (800)-782-1768 Email: sales@verifiedmarketresearch.com Web: https://www.verifiedmarketresearch.com/ BI Enabled Platform: https://www.verifiedmarketresearch.com/vmintelligence/ Follow Us: LinkedIn | Twitter